Literature DB >> 23560456

Tissue factor activity and ECM-related gene expression in human aortic endothelial cells grown on electrospun biohybrid scaffolds.

Jingjia Han1, Jonathan A Gerstenhaber, Philip Lazarovici, Peter I Lelkes.   

Abstract

All blood vessels are lined with a quiescent endothelium, which aids in regulating regular blood flow and avoiding thrombus formation. Current attempts at replacing diseased blood vessels frequently fail due to the intrinsic thrombogenicity of the materials used as vascular grafts. In extending our previous work where we introduced a new candidate scaffolds for vascular grafts electrospun from a blend solution of PLGA, gelatin, and elastin (PGE), this study aimed to evaluate the potential of PGE scaffolds to support nonthrombogenic monolayers of primary isolates of human aortic endothelial cells (HAECs), as assessed by a combination of biochemical, molecular, and bioinformatics-based analyses. After 24 h of culture on 3-D fibrous PGE scaffolds, HAECs formed a confluent, nonthrombogenic, and physiologically competent monolayer, as assessed by tissue factor (TF) gene expression and protein activity assays. The levels of TF mRNA/protein activity in HAECs grown on PGE scaffolds were similar to those on gelatin or collagen IV-coated 2-D surfaces. In addition, bioinformatics-based analysis of a focused microarray containing 84 ECM-related cDNA probes demonstrated that HAECs essentially expressed a histotypic ECM-related "transcriptome" on PGE scaffolds, where cells were more quiescent than cells cultured on 2-D coverslips coated with gelatin (a well-known "inert" substrate for conventional EC culture), but less so than on 2-D PGE films. These data suggest an important role for nanorough substrates (PGE films) in passivating endothelial cells and confirm the crucial effect of substrate composition in this process. Principal component analysis of microarray data on the above substrates (including collagen IV) implied that substrate composition plays a greater role than surface topography in affecting the endothelial ECM-related "transcriptome". Taken together, our findings suggest that electrospun PGE scaffolds are potentially suitable for application in small diameter vascular tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23560456     DOI: 10.1021/bm400450m

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  6 in total

Review 1.  Extracellular Matrix-Based Biohybrid Materials for Engineering Compliant, Matrix-Dense Tissues.

Authors:  Laura G Bracaglia; John P Fisher
Journal:  Adv Healthc Mater       Date:  2015-07-30       Impact factor: 9.933

2.  Hybrid cardiovascular sourced extracellular matrix scaffolds as possible platforms for vascular tissue engineering.

Authors:  James A Reid; Anthony Callanan
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2019-08-01       Impact factor: 3.368

3.  Modulating electrospun polycaprolactone scaffold morphology and composition to alter endothelial cell proliferation and angiogenic gene response.

Authors:  James Alexander Reid; Alison McDonald; Anthony Callanan
Journal:  PLoS One       Date:  2020-10-08       Impact factor: 3.240

4.  Three-Dimensional Poly-(ε-Caprolactone) Nanofibrous Scaffolds Promote the Maturation of Human Pluripotent Stem Cells-Induced Cardiomyocytes.

Authors:  Mingming Zhang; Yuerong Xu; Yan Chen; Qinru Yan; Xiaoli Li; Lu Ding; Ting Wei; Di Zeng
Journal:  Front Cell Dev Biol       Date:  2022-08-01

5.  Cell alignment induced by anisotropic electrospun fibrous scaffolds alone has limited effect on cardiomyocyte maturation.

Authors:  Jingjia Han; Qingling Wu; Younan Xia; Mary B Wagner; Chunhui Xu
Journal:  Stem Cell Res       Date:  2016-04-18       Impact factor: 2.020

6.  Nanofiber Alignment Regulates NIH3T3 Cell Orientation and Cytoskeletal Gene Expression on Electrospun PCL+Gelatin Nanofibers.

Authors:  Timothy Fee; Swetha Surianarayanan; Crawford Downs; Yong Zhou; Joel Berry
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.